Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal Diseases by Promoting Regeneration of Bowel Architecture – – Interim Results From Phase 2 CALLIPER Trial of Vidofludimus Calcium…